Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer
靶向免疫抑制腺苷治疗转移性非小细胞肺癌患者
基本信息
- 批准号:10593117
- 负责人:
- 金额:$ 38.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-01 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:AblationAdenosineAdenosine A2B ReceptorAdverse effectsAffectAffinityAnimal ModelAnimalsApplications GrantsBiologyBiopsyCancer ModelCancer PatientCatabolismCell Differentiation processCell FractionCellsClinical ResearchClinical TrialsCollaborationsCombination immunotherapyCombined Modality TherapyDataDendritic CellsDiseaseDoseEffectivenessEnzymesEvaluationGenerationsGeneticGrowthImmuneImmune checkpoint inhibitorImmunityImmunologicsImmunosuppressionImmunotherapeutic agentImmunotherapyImpairmentInstitutionMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of lungMaximum Tolerated DoseMediatingMetabolicMetabolic stressMethodsModelingMolecularMyelogenousMyeloid-derived suppressor cellsNatural Killer CellsNivolumabNon-Small-Cell Lung CarcinomaOutcomePD-1 inhibitorsPathologicPatientsPeripheral Blood Mononuclear CellPhasePhase Ib Clinical TrialPhase Ib TrialPhenotypePreclinical Drug EvaluationProbabilityProductivityProteinsPurinergic P1 ReceptorsReceptor InhibitionReceptor SignalingRecommendationRegulationRegulatory T-LymphocyteResistanceRoleSafetySamplingShapesSignal TransductionSpainT cell responseT-LymphocyteTestingTissuesTumor Immunityantagonistanti-PD-1anti-PD1 antibodiesanti-tumor immune responseblood treatmentcheckpoint inhibitionchemotherapyclinical applicationcohortdesignecto-nucleotidaseefficacy evaluationextracellularimaging approachimaging modalityimmunoregulationimprovednovelnovel strategiesnovel therapeutic interventionpharmacologicphenotypic biomarkerpre-clinicalpreclinical studyprogrammed cell death protein 1receptorresponsesafety assessmentstress reductiontherapeutic targettumortumor growthtumor microenvironment
项目摘要
SUMMARY/ABSTRACT
Immune checkpoint inhibitors (ICIs) have transformed the management of patients with metastatic non-small cell
lung cancer (NSCLC). Unfortunately, over 50% of patients do not respond to these therapies. Combination
strategies with chemotherapy-ICIs show progress, but long-term responses remain rare, pointing to the role for
other tumor-associated mechanisms affecting functionality of immune cells. Adenosinergic signaling has recently
emerged as a powerful immuno-metabolic regulator within the tumor microenvironment (TME) exploited by
tumors to promote their growth and suppress immunity. Preclinical studies on interference with adenosine
generation or signaling through A2A and A2B adenosine receptors (A2BAR) have demonstrated efficacy in relieving
this immunosuppression by reducing stress in the TME and decreasing expression of key adenosine-generating
enzymes, thereby enhancing efficacy of immune checkpoint inhibition. A2BAR blockade in particular enhanced
anti-tumor immunity through both a reduction in myeloid-derived suppressor cell differentiation and an
enhancement of the capacity of dendritic cells to evoke anti-tumor T cell responses. These findings provide
strong rationale for clinical applications of A2BAR antagonists in combination with current ICIs. To determine
whether disruption of A2BAR signaling has the potential to improve upon single agent PD-1 immunotherapy, we
propose a phase Ib clinical trial testing the A2BAR antagonist PBF-1129 in combination with nivolumab in
patients with metastatic NSCLC. The primary objective of the clinical study is to evaluate the safety and
tolerability of combination PBF-1129 with nivolumab; preliminary evidence of efficacy will be evaluated in an
expansion cohort. Analysis of pre- and on- treatment blood and tumor samples will be conducted to evaluate the
correlation between and immunological parameters and adenosine generation and signaling, and to evaluate
the efficacy of PBF-1129 in targeting adenosine-mediated immunosuppression. Finally, we intend to further
elucidate mechanisms of metabolic TME and immune regulation by adenosine in pre-clinical cancer models and
test the combined PBF-1129/anti-PD-1 approach to ameliorate metabolic TME using a novel imaging modality.
Together, we expect that A2BAR antagonist treatment combined with nivolumab will be a safe, effective
approach targeting different mechanisms of immunosuppression and tumor growth in metastatic
NSCLC patients, that we will uncover immunological profiles reflective of adenosinergic signaling
disruption in these patients, and that we will demonstrate the utility of a novel combined imaging
approach for evaluation of adenosine targeting in the TME.
摘要/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID P. CARBONE其他文献
DAVID P. CARBONE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID P. CARBONE', 18)}}的其他基金
Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer
靶向免疫抑制腺苷治疗转移性非小细胞肺癌患者
- 批准号:
10350636 - 财政年份:2021
- 资助金额:
$ 38.05万 - 项目类别:
OSU as a Network Lead Academic Participating Site for the NCI NCTN
OSU 作为 NCI NCTN 网络主导学术参与网站
- 批准号:
9902398 - 财政年份:2019
- 资助金额:
$ 38.05万 - 项目类别:
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
ECOG-ACRIN 胸部恶性肿瘤综合转化科学中心
- 批准号:
10374819 - 财政年份:2019
- 资助金额:
$ 38.05万 - 项目类别:
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
ECOG-ACRIN 胸部恶性肿瘤综合转化科学中心
- 批准号:
9894764 - 财政年份:2019
- 资助金额:
$ 38.05万 - 项目类别:
OSU as a Network Lead Academic Participating Site for the NCI NCTN
OSU 作为 NCI NCTN 网络主导学术参与网站
- 批准号:
10581614 - 财政年份:2019
- 资助金额:
$ 38.05万 - 项目类别:
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
ECOG-ACRIN 胸部恶性肿瘤综合转化科学中心
- 批准号:
10133005 - 财政年份:2019
- 资助金额:
$ 38.05万 - 项目类别:
OSU as a Network Lead Academic Participating Site for the NCI NCTN
OSU 作为 NCI NCTN 网络主导学术参与网站
- 批准号:
10356923 - 财政年份:2019
- 资助金额:
$ 38.05万 - 项目类别:
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
ECOG-ACRIN 胸部恶性肿瘤综合转化科学中心
- 批准号:
10582677 - 财政年份:2019
- 资助金额:
$ 38.05万 - 项目类别:
Notch ligands in regulation of anti-cancer immunity
Notch配体在抗癌免疫调节中的作用
- 批准号:
8743193 - 财政年份:2013
- 资助金额:
$ 38.05万 - 项目类别:
Notch ligands in regulation of anti-cancer immunity
Notch配体在抗癌免疫调节中的作用
- 批准号:
9130120 - 财政年份:2013
- 资助金额:
$ 38.05万 - 项目类别:
相似国自然基金
基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
- 批准号:82074359
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
- 批准号:81570244
- 批准年份:2015
- 资助金额:57.0 万元
- 项目类别:面上项目
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制
- 批准号:81171113
- 批准年份:2011
- 资助金额:55.0 万元
- 项目类别:面上项目
相似海外基金
Studies on the role of adenosine A2B receptor in visceral hypersensitivity
腺苷A2B受体在内脏过敏中作用的研究
- 批准号:
18K15033 - 财政年份:2018
- 资助金额:
$ 38.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Are pulmonary GABA-receptors the key for the therapy of acute pulmonary inflammation and does the link with the adenosine A2B-receptor represent the first step towards personalized medicine?
肺部 GABA 受体是治疗急性肺部炎症的关键吗?与腺苷 A2B 受体的联系是否代表着个体化医疗的第一步?
- 批准号:
398748271 - 财政年份:2018
- 资助金额:
$ 38.05万 - 项目类别:
Research Grants
Adenosine A2B Receptor in Bone Health and Osteoporosis
腺苷 A2B 受体在骨骼健康和骨质疏松症中的作用
- 批准号:
9551206 - 财政年份:2017
- 资助金额:
$ 38.05万 - 项目类别:
Characterization of intestinal adenosine A2b receptor
肠腺苷 A2b 受体的表征
- 批准号:
6669814 - 财政年份:2003
- 资助金额:
$ 38.05万 - 项目类别:
Characterization of intestinal adenosine A2b receptor
肠腺苷 A2b 受体的表征
- 批准号:
6802024 - 财政年份:2003
- 资助金额:
$ 38.05万 - 项目类别: